In addition, the study showed that the 5 - year survival rate for selected older patients
with advanced lung cancer who were treated with surgical therapy was 29.9 % for Stage III and 26.7 % for Stage IV.
Without immunotherapy, the five year survival rate is only one percent in a study of 129 patients
with advanced lung cancer.
«Chemotherapy may be better for certain patients
with advanced lung cancer.»
Pembrolizumab is set to become a new option for first line treatment of patients
with advanced lung cancer and high PD - L1 expression, according to the results of the phase III KEYNOTE - 024 trial presented at the ESMO 2016 Congress in Copenhagen and published in the New England Journal of Medicine.
«Rapid advancements in genetic testing offer new treatment options for patients
with advanced lung cancer.
Geneva, Switzerland, 05 May 2017 — Osimertinib improves cancer - related symptoms in patients
with advanced lung cancer, according to an analysis of patient - reported outcomes from the AURA3 phase III clinical trial presented today at the European Lung Cancer Conference.
Merck's Keytruda showed promise in its latest trial in prolonging survival rates among patients
with advanced lung cancer.